Avalo Therapeutics announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. Dr. Doyle is a proven research physician who brings over 20 years of experience in the pharmaceutical/biotech industry and has held numerous leadership roles in clinical development. Dr. Doyle joins Avalo from Aro Biotherapeutics where she served as Chief Medical Officer since 2021.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics announces active IND for AVTX-009
- Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
- Avalo Therapeutics Welcomes New Chief Legal Officer Paul Varki
- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
- Avalo Therapeutics announces Paul Varki joins as Chief Legal Officer